Recent developments highlight Pulmonx’s 6% revenue growth in Q3 2026, narrowing losses, sales force rebuilding, and plans for a new product launch. The company’s stock has experienced notable gains amid positive sector momentum.

• Pulmonx reported 6% revenue growth in Q3 2026, narrowed losses, and maintained its 2026 revenue outlook [N1].
• The company’s Q3 2026 earnings call detailed operational progress and strategic initiatives [N3][N4].
• Pulmonx’s Q3 2026 results showed a net loss but topped revenue estimates [N5].
• Pulmonx is rebuilding its sales force and targeting growth with a planned launch of the AeriSeal product next year [N6].
• The stock gained over 30% recently amid broader biotech sector strength [N2].
• Q2 2026 earnings call and results showed narrowed losses and margin gains, supporting operational momentum [N7][N8].

Pulmonx’s focused strategy on severe emphysema treatment with the Zephyr Valve, combined with ongoing sales force expansion and direct-to-patient marketing, supports incremental adoption in a specialized market. The company’s efforts to build emphysema centers of excellence and educate physicians across disciplines may increase procedure volumes. The planned launch of AeriSeal could diversify the product portfolio and open new revenue streams. Recent quarterly results showing revenue growth and narrowed losses indicate operational progress. Positive coverage policies with major payors and ongoing clinical data generation may enhance reimbursement and market acceptance over time [N1][N6][S2].

Pulmonx faces significant risks including continued net losses and the need for substantial additional capital to fund operations. The company’s reliance on a single product with limited indications exposes it to market adoption risks. Challenges in securing hospital contracts, physician training, and reimbursement coverage may constrain sales growth. Potential procedural complications and limited long-term safety data could hinder physician and patient acceptance. Competitive pressures from alternative therapies and declining COPD patient populations due to reduced smoking rates may limit market size. Fluctuating operating results and regulatory uncertainties add to execution risks [S1][S2].

Pulmonx’s competitive moat is primarily based on its proprietary Zephyr Endobronchial Valve technology, regulatory approvals for treatment of severe emphysema, and established relationships with pulmonologists and hospitals. The company’s early market entry and specialized training programs for physicians create barriers to entry for competitors. Additionally, the integration of the Zephyr Valve with supporting systems like the Chartis System enhances its clinical utility. However, the moat is limited by the narrow indication scope, reliance on a single product, and the evolving reimbursement landscape. The need for physician training and hospital contracting processes also create switching costs and adoption barriers that support Pulmonx’s market position [S1][S2].

• Continued Net Losses and Capital Needs: Pulmonx has a history of significant net losses and expects to incur additional losses, requiring substantial capital to finance operations. Failure to secure financing on acceptable terms could limit commercialization and development efforts [S2].
• Single Product Dependency: The business depends entirely on the Zephyr Valve, which has limited approved indications. Failure to commercialize this product successfully or develop additional products could negatively impact financial results [S1][S2].
• Market Adoption Challenges: Adoption depends on hospital, physician, and patient willingness to change treatment practices. Barriers include physician training, reimbursement variability, hospital contracting, and competition from alternative therapies [S1][S2].
• Reimbursement and Coverage Risks: Inconsistent coverage policies and administrative burdens may limit patient access and physician willingness to recommend the Zephyr Valve, affecting sales [S1][S2].
• Procedural Risks and Limited Long-Term Data: Use of the Zephyr Valve involves risks such as pneumothorax and is contraindicated in some patients. Limited long-term safety and effectiveness data may restrict adoption [S1][S2].
• Regulatory and Manufacturing Risks: Delays or failures in obtaining regulatory approvals for new products or indications, and manufacturing challenges, could adversely affect operations and margins [S1][S2].

• Pulmonx Corp is a medical device company focused on commercializing the Zephyr Endobronchial Valve, a minimally invasive treatment for severe emphysema, a form of COPD [S1][S2].
• The Zephyr Valve is currently the company's sole marketed product and is approved for limited indications primarily in the United States and some international markets [S1][S2].
• Pulmonx also sells and rents the Chartis System and catheters used for delivery of the Zephyr Valve, but these are dependent on Zephyr Valve sales [S1][S2].
• The company began commercializing the Zephyr Valve in the US in 2018 and earlier in Europe through predecessors [S1].
• Pulmonx’s business model depends heavily on hospital, physician, and patient adoption of the Zephyr Valve as a treatment alternative to existing therapies for severe emphysema [S1][S2].
• The company invests in sales force expansion, physician education, and direct-to-patient marketing to increase adoption and build emphysema centers of excellence [S1][S2][N6].
• Pulmonx faces risks related to limited long-term safety and effectiveness data, potential complications from the procedure, and contraindications limiting patient eligibility [S1][S2].
• Reimbursement and coverage by payors, including Medicare and commercial insurers, are variable and can affect adoption and sales [S1][S2].
• The company has a history of net losses, with a net loss of $8.394 million for Q3 2026 and accumulated deficit of $553.7 million as of September 30, 2026 [S2].
• Liquidity as of September 30, 2026 includes $52.69 million in cash and equivalents, current assets of $84.06 million, current liabilities of $20.74 million, with a current ratio of 4.05 and cash ratio of 2.54 [S2].
• Pulmonx reported 6% revenue growth in Q3 2026 and narrowed losses compared to prior periods [N1][N5].
• The company is rebuilding its sales force and targeting growth with a planned launch of a new product, AeriSeal, next year [N6].
• Recent news highlights include strong stock price gains and positive market interest in Pulmonx and its sector peers [N2].
• The company’s operating results may fluctuate significantly due to factors including sales force effectiveness, regulatory approvals, reimbursement environment, and market adoption [S1][S2].
• Pulmonx’s sales cycle involves hospital purchasing contracts and bidding processes that can be lengthy and uncertain, potentially impacting sales [S1][S2].
• Physician training and proper use of the Zephyr Valve are critical to patient outcomes and market acceptance [S1][S2].